Platform Selection and Development Strategies for High-Performance Anti-Idiotype Antibody Development – in Just 9 Weeks
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Therapeutic antibodies are a rapidly growing class of drugs. Their application areas are not only limited to the standard immunoglobulin G (IgG) format but can also be extended to novel formats, including antibody fragments (scFv, VHH), drug conjugates and bispecifics. This webinar explores platform selection and development strategies for generating high-performance anti-idiotype (anti-ID) antibodies to support pharmacokinetic (PK) and anti-drug antibody (ADA) assays.
To ensure their safety and efficacy, regulatory agencies and pharmaceutical developers rely on two essential types of assays: PK assays and ADA assays. PK measures how a drug is absorbed, distributed, metabolized and eliminated in the body. ADA assays are designed to detect and measure the immunogenicity of an antibody drug after treatment.
Anti-ID antibodies bind to the idiotype, a specific epitope group on the variable region, of another antibody, usually an antibody drug. High-performance anti-IDs are critical for developing sensitive, specific and robust PK and ADA assays to support pre-clinical and clinical studies in drug development programs. High sensitivity and specificity, strong affinity and well-defined epitope-binding specificity are important features for anti-IDs.
Rabbit monoclonal antibodies (mAbs) are known for their high affinity and diversity, making them a valuable source of highly specialized research reagents. The lower homology of the antibody drug to rabbit germline sequences compared with mice suggests that rabbits may generally mount a stronger immune response to an antibody drug than mice. An optimized rabbit B cell cloning platform can support the discovery of high-quality anti-IDs with high sequence diversity and affinity, including blocker and non-blocker antibodies.
Register for this webinar to learn how anti-idiotype antibody development strategies can support sensitive, specific PK and ADA assays.
Who should attend
- Pharmacokinetic Assay Development
- ADA Assay Development
- Antibody Drug Discovery
- Cell and Gene Therapy
- Pharma/biotech conducting late pre-clinical studies/clinical studies
What you will learn
- Why anti-IDs fail and the downstream impact on PK and ADA programs
- How to select the optimal anti-ID discovery platform and strategy for different drug targets
- How blocker and non-blocker anti-IDs can be generated and evaluated through case studies
Featured Speakers
Zhihao Li
Zhihao Li, Senior Scientist in the Antibody Development Department at GenScript Biotech Corporation, holds a PhD in Biological Sciences from Tsinghua University and has over five years of experience in monoclonal antibody development. He is responsible for the technical optimization of the monoclonal antibody platform, as well as the evaluation and troubleshooting of challenging monoclonal antibody development projects.
Partner for this event
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to make people and nature healthier through biotechnology by scripting possibilities.